Logo image of IFRX

INFLARX NV (IFRX) Stock Price, Quote, News and Overview

NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD

1.84  -0.07 (-3.66%)

IFRX Quote, Performance and Key Statistics

INFLARX NV

NASDAQ:IFRX (2/20/2025, 2:53:25 PM)

1.84

-0.07 (-3.66%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.82
52 Week Low1.17
Market Cap108.34M
Shares58.88M
Float54.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-19 2025-03-19/amc
IPO11-16 2017-11-16


IFRX short term performance overview.The bars show the price performance of IFRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

IFRX long term performance overview.The bars show the price performance of IFRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20

The current stock price of IFRX is 1.84 USD. In the past month the price decreased by -22.87%. In the past year, price increased by 26.16%.

INFLARX NV / IFRX Daily stock chart

IFRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.81 354.33B
AMGN AMGEN INC 14.9 158.54B
GILD GILEAD SCIENCES INC 23.76 136.46B
VRTX VERTEX PHARMACEUTICALS INC 1652.45 123.11B
REGN REGENERON PHARMACEUTICALS 15.2 75.85B
ARGX ARGENX SE - ADR N/A 39.34B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.39B
BNTX BIONTECH SE-ADR N/A 27.99B
ONC BEIGENE LTD-ADR N/A 25.80B
NTRA NATERA INC N/A 22.03B
BIIB BIOGEN INC 8.33 20.00B
SMMT SUMMIT THERAPEUTICS INC N/A 16.87B

About IFRX

Company Profile

IFRX logo image InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 66 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Company Info

INFLARX NV

Winzerlaer Str. 2

Jena THUERINGEN 07745 DE

CEO: Niels Riedemann

Employees: 62

Company Website: https://www.inflarx.de/

Investor Relations: http://www.inflarx.de/Home/Investors/Financial-Information.html

Phone: 493641508180

INFLARX NV / IFRX FAQ

What is the stock price of INFLARX NV today?

The current stock price of IFRX is 1.84 USD. The price decreased by -3.66% in the last trading session.


What is the ticker symbol for INFLARX NV stock?

The exchange symbol of INFLARX NV is IFRX and it is listed on the Nasdaq exchange.


On which exchange is IFRX stock listed?

IFRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INFLARX NV stock?

12 analysts have analysed IFRX and the average price target is 8.77 USD. This implies a price increase of 376.74% is expected in the next year compared to the current price of 1.84. Check the INFLARX NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INFLARX NV worth?

INFLARX NV (IFRX) has a market capitalization of 108.34M USD. This makes IFRX a Micro Cap stock.


How many employees does INFLARX NV have?

INFLARX NV (IFRX) currently has 62 employees.


What are the support and resistance levels for INFLARX NV (IFRX) stock?

INFLARX NV (IFRX) has a support level at 1.9 and a resistance level at 2.37. Check the full technical report for a detailed analysis of IFRX support and resistance levels.


Is INFLARX NV (IFRX) expected to grow?

The Revenue of INFLARX NV (IFRX) is expected to decline by -93.22% in the next year. Check the estimates tab for more information on the IFRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INFLARX NV (IFRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INFLARX NV (IFRX) stock pay dividends?

IFRX does not pay a dividend.


When does INFLARX NV (IFRX) report earnings?

INFLARX NV (IFRX) will report earnings on 2025-03-19, after the market close.


What is the Price/Earnings (PE) ratio of INFLARX NV (IFRX)?

INFLARX NV (IFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).


What is the Short Interest ratio of INFLARX NV (IFRX) stock?

The outstanding short interest for INFLARX NV (IFRX) is 0.76% of its float. Check the ownership tab for more information on the IFRX short interest.


IFRX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to IFRX. When comparing the yearly performance of all stocks, IFRX turns out to be only a medium performer in the overall market: it outperformed 69.42% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IFRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IFRX. The financial health of IFRX is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IFRX Financial Highlights

Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS decreased by -40% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -71.38%
ROE -87.13%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-130.77%
Sales Q2Q%103.95%
EPS 1Y (TTM)-40%
Revenue 1Y (TTM)177.15%

IFRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to IFRX. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -22.14% and a revenue growth -93.22% for IFRX


Ownership
Inst Owners22.61%
Ins Owners7.33%
Short Float %0.76%
Short Ratio1.16
Analysts
Analysts85
Price Target8.77 (376.63%)
EPS Next Y-22.14%
Revenue Next Year-93.22%